Covered recipient · General Payments record
MANISH SHARMA
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$185.35
5 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $185.35 | 5 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme Corporation | $114.12 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $32.95 | 2 |
| Adaptive Biotechnologies Corporation | $20.54 | 1 |
| Jazz Pharmaceuticals Inc. | $17.74 | 1 |
Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MANISH SHARMA
NPI 1790819332 · CMS profile ID 1126262
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
GRAND RAPIDS, MI
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1790819332?year=2020&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1790819332?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1790819332?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- MANISH SHARMA, NPI 1790819332, CMS profile ID 1126262, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1790819332?year=2020&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
5 matching records · $185.35 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–5 of 5.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Adaptive Biotechnologies Corporation | $20.54 | 04/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751728339 | CMS |
| Jazz Pharmaceuticals Inc. | $17.74 | 03/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744453069 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $13.97 | 03/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 713650555 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $18.98 | 02/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 713644195 | CMS |
| Merck Sharp & Dohme Corporation | $114.12 | 01/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747615597 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $373.20 | 2 |
| PY2025 | Principal investigator | $4,235,582.65 | 823 |
| PY2024 | Recipient | $4,269.33 | 9 |
| PY2024 | Principal investigator | $3,811,534.65 | 643 |
| PY2023 | Recipient | $3,810.00 | 6 |
| PY2023 | Principal investigator | $3,149,687.09 | 471 |
| PY2022 | Principal investigator | $3,302,171.04 | 339 |
| PY2021 | Recipient | $7,293.02 | 4 |
| PY2021 | Principal investigator | $2,076,760.51 | 208 |
| PY2020 | Recipient | $7,900.00 | 2 |
| PY2020 | Principal investigator | $1,132,655.23 | 78 |
| PY2019 | Principal investigator | $1,305,040.24 | 61 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
477 records in PY2023
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $439.00 | 12/31/2023 | Non-covered Recipient Entity START MIDWEST | Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and is associated with poor prognosis and limited treatment options. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors | No dispute reported | 06/30/2026 | 998415163 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $510.17 | 12/31/2023 | Non-covered Recipient Entity CANCER AND HEMATOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | No dispute reported | 06/30/2026 | 991131711 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $85,200.00 | 12/28/2023 | Non-covered Recipient Entity START Midwest | A Phase 1,1b Dose Escalation,Expansion Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1042566921 |
| Principal investigator 1 | PFIZER INC. | $49,103.08 | 12/22/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046420167 |
| Principal investigator 1 | PFIZER INC. | $9,105.76 | 12/22/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046440261 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,970.00 | 12/21/2023 | Non-covered Recipient Entity START MIDWEST | AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB | No dispute reported | 06/30/2026 | 1006132773 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $170,400.00 | 12/15/2023 | Non-covered Recipient Entity South Texas Accelerated Research Therapeutics START Midwest | A Phase 1,1b Dose Escalation,Expansion Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1042567621 |
| Principal investigator 1 | PFIZER INC. | $5,078.70 | 12/09/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046366233 |
| Principal investigator 1 | PFIZER INC. | $3,368.25 | 12/08/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1046417263 |
| Principal investigator 1 | PFIZER INC. | $1,677.71 | 12/07/2023 | Non-covered Recipient Entity START Midwest LLC | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046366083 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $28,140.60 | 12/06/2023 | Non-covered Recipient Entity MULTIPLE DOCTORS | AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD | No dispute reported | 06/30/2026 | 1006132807 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 12/04/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998410173 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 12/04/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998410175 |
| Principal investigator 1 | MACROGENICS, INC. | $1,173.79 | 12/04/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043830853 |
| Principal investigator 1 | MACROGENICS, INC. | $1,671.76 | 12/04/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043830867 |
| Principal investigator 1 | MACROGENICS, INC. | $711.39 | 12/04/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043830881 |
| Principal investigator 1 | Genmab U.S., Inc. | $3,924.48 | 11/29/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392165 |
| Principal investigator 1 | PFIZER INC. | $22,235.86 | 11/25/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046392727 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,088.36 | 11/22/2023 | Non-covered Recipient Entity START MIDWEST | AN OPEN-LABEL, MULTICENTER, LONG-TERM TREATMENT EXTENSION STUDY IN SUB | No dispute reported | 06/30/2026 | 1006132783 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $234,300.00 | 11/21/2023 | Non-covered Recipient Entity START Midwest | An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1042565935 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $18,480.00 | 11/10/2023 | Non-covered Recipient Entity MULTIPLE DOCTORS | AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD | No dispute reported | 06/30/2026 | 1006132863 |
| Principal investigator 1 | PFIZER INC. | $7,667.67 | 11/04/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046405207 |
| Principal investigator 1 | MACROGENICS, INC. | $2,510.65 | 10/31/2023 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST | MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER | No dispute reported | 06/30/2026 | 1043829543 |
| Principal investigator 1 | MACROGENICS, INC. | $1,068.36 | 10/31/2023 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST | MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER | No dispute reported | 06/30/2026 | 1043829557 |
| Principal investigator 1 | MACROGENICS, INC. | $1,762.79 | 10/31/2023 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST | MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER | No dispute reported | 06/30/2026 | 1043829569 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 10/30/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998405437 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 10/26/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998404959 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 10/26/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998404961 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 10/26/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998404963 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 10/26/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998404991 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 10/26/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998405121 |
| Principal investigator 1 | PFIZER INC. | $7,443.23 | 10/24/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046397005 |
| Principal investigator 1 | PFIZER INC. | $2,400.30 | 10/24/2023 | Non-covered Recipient Entity START Midwest LLC | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046423733 |
| Principal investigator 1 | MACROGENICS, INC. | $6,689.63 | 10/23/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043829225 |
| Principal investigator 1 | MACROGENICS, INC. | $2,846.65 | 10/23/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043829237 |
| Principal investigator 1 | MACROGENICS, INC. | $4,696.97 | 10/23/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043829251 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,573.00 | 10/18/2023 | Non-covered Recipient Entity MULTIPLE DOCTORS | AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD | No dispute reported | 06/30/2026 | 1006132839 |
| Principal investigator 1 | PFIZER INC. | $108.00 | 10/18/2023 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046370943 |
| Principal investigator 1 | PFIZER INC. | $650.00 | 10/16/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046377467 |
| Principal investigator 1 | PFIZER INC. | $27,945.94 | 10/12/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046397247 |
| Principal investigator 1 | PFIZER INC. | $71,437.67 | 10/12/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046427459 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 10/02/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998401497 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 10/02/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998401499 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 10/02/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998401501 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 10/02/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998401561 |
| Principal investigator 1 | PFIZER INC. | $325.00 | 10/02/2023 | Non-covered Recipient Entity START Midwest | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046395797 |
| Principal investigator 1 | PFIZER INC. | $32,356.51 | 09/22/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046387981 |
| Principal investigator 1 | PFIZER INC. | $2,400.30 | 09/22/2023 | Non-covered Recipient Entity START Midwest LLC | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046407141 |
| Principal investigator 1 | PFIZER INC. | $14,104.97 | 09/05/2023 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046376661 |
| Principal investigator 1 | PFIZER INC. | $650.00 | 09/05/2023 | Non-covered Recipient Entity START Midwest | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046380011 |
| Principal investigator 1 | PFIZER INC. | $63.00 | 09/05/2023 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046380633 |
| Principal investigator 1 | PFIZER INC. | $13,394.04 | 09/02/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046386803 |
| Principal investigator 1 | PFIZER INC. | $16,279.40 | 09/02/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046408147 |
| Principal investigator 1 | PFIZER INC. | $2,400.30 | 08/31/2023 | Non-covered Recipient Entity START Midwest LLC | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046431021 |
| Principal investigator 1 | PFIZER INC. | $1,300.00 | 08/28/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046374997 |
| Principal investigator 1 | ABBVIE INC. | $1,691.28 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396667 |
| Principal investigator 1 | ABBVIE INC. | $1,472.85 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396669 |
| Principal investigator 1 | ABBVIE INC. | $1,034.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396671 |
| Principal investigator 1 | ABBVIE INC. | $1,552.50 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396673 |
| Principal investigator 1 | ABBVIE INC. | $4,209.17 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396675 |
| Principal investigator 1 | ABBVIE INC. | $2,408.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396677 |
| Principal investigator 1 | ABBVIE INC. | $1,552.50 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396679 |
| Principal investigator 1 | ABBVIE INC. | $2,941.52 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396681 |
| Principal investigator 1 | ABBVIE INC. | $1,208.25 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396683 |
| Principal investigator 1 | ABBVIE INC. | $2,941.52 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396685 |
| Principal investigator 1 | ABBVIE INC. | $2,941.52 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396687 |
| Principal investigator 1 | ABBVIE INC. | $4,209.17 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396689 |
| Principal investigator 1 | ABBVIE INC. | $2,062.53 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396703 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396705 |
| Principal investigator 1 | ABBVIE INC. | $2,408.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396707 |
| Principal investigator 1 | ABBVIE INC. | $1,691.28 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396709 |
| Principal investigator 1 | ABBVIE INC. | $1,552.50 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396711 |
| Principal investigator 1 | ABBVIE INC. | $3,002.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396713 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396715 |
| Principal investigator 1 | ABBVIE INC. | $4,209.17 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396717 |
| Principal investigator 1 | ABBVIE INC. | $2,408.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396719 |
| Principal investigator 1 | ABBVIE INC. | $2,941.52 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396721 |
| Principal investigator 1 | ABBVIE INC. | $1,113.75 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396727 |
| Principal investigator 1 | ABBVIE INC. | $3,002.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396729 |
| Principal investigator 1 | ABBVIE INC. | $2,941.52 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396731 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396733 |
| Principal investigator 1 | ABBVIE INC. | $1,472.85 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396735 |
| Principal investigator 1 | ABBVIE INC. | $1,968.03 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396737 |
| Principal investigator 1 | ABBVIE INC. | $1,552.50 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396739 |
| Principal investigator 1 | ABBVIE INC. | $2,941.52 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396741 |
| Principal investigator 1 | ABBVIE INC. | $2,062.53 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396743 |
| Principal investigator 1 | ABBVIE INC. | $1,691.28 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396745 |
| Principal investigator 1 | ABBVIE INC. | $2,062.53 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396747 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396749 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396751 |
| Principal investigator 1 | ABBVIE INC. | $2,062.53 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396753 |
| Principal investigator 1 | ABBVIE INC. | $2,941.52 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396755 |
| Principal investigator 1 | ABBVIE INC. | $3,002.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396763 |
| Principal investigator 1 | ABBVIE INC. | $4,209.17 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396765 |
| Principal investigator 1 | ABBVIE INC. | $1,472.85 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396767 |
| Principal investigator 1 | ABBVIE INC. | $500.85 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396769 |
| Principal investigator 1 | ABBVIE INC. | $2,718.77 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396771 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396773 |
| Principal investigator 1 | ABBVIE INC. | $1,472.85 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396775 |
| Principal investigator 1 | ABBVIE INC. | $1,968.03 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396777 |
| Principal investigator 1 | ABBVIE INC. | $4,209.17 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396779 |
| Principal investigator 1 | ABBVIE INC. | $1,472.85 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396781 |
| Principal investigator 1 | ABBVIE INC. | $2,713.37 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396783 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396785 |
| Principal investigator 1 | ABBVIE INC. | $2,934.77 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396787 |
| Principal investigator 1 | ABBVIE INC. | $2,408.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396789 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396791 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396793 |
| Principal investigator 1 | ABBVIE INC. | $1,691.28 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396813 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396815 |
| Principal investigator 1 | ABBVIE INC. | $2,062.53 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396817 |
| Principal investigator 1 | ABBVIE INC. | $1,034.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396819 |
| Principal investigator 1 | ABBVIE INC. | $2,718.77 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396821 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396823 |
| Principal investigator 1 | ABBVIE INC. | $3,002.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396825 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396827 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396829 |
| Principal investigator 1 | ABBVIE INC. | $1,552.50 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396831 |
| Principal investigator 1 | ABBVIE INC. | $1,113.75 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396833 |
| Principal investigator 1 | ABBVIE INC. | $1,113.75 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396835 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396837 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396839 |
| Principal investigator 1 | ABBVIE INC. | $1,691.28 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396841 |
| Principal investigator 1 | ABBVIE INC. | $3,002.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396843 |
| Principal investigator 1 | ABBVIE INC. | $2,062.53 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396859 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396861 |
| Principal investigator 1 | ABBVIE INC. | $1,034.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396863 |
| Principal investigator 1 | ABBVIE INC. | $1,691.28 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396865 |
| Principal investigator 1 | ABBVIE INC. | $1,113.75 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396867 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396869 |
| Principal investigator 1 | ABBVIE INC. | $1,968.03 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396871 |
| Principal investigator 1 | ABBVIE INC. | $1,113.75 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396873 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396875 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396877 |
| Principal investigator 1 | ABBVIE INC. | $1,968.03 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396879 |
| Principal investigator 1 | ABBVIE INC. | $1,208.25 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396881 |
| Principal investigator 1 | ABBVIE INC. | $2,718.77 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396883 |
| Principal investigator 1 | ABBVIE INC. | $2,941.52 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396885 |
| Principal investigator 1 | ABBVIE INC. | $1,472.85 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396901 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396903 |
| Principal investigator 1 | ABBVIE INC. | $1,552.50 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396905 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396907 |
| Principal investigator 1 | ABBVIE INC. | $2,718.77 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396909 |
| Principal investigator 1 | ABBVIE INC. | $3,002.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396911 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396913 |
| Principal investigator 1 | ABBVIE INC. | $2,062.53 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396915 |
| Principal investigator 1 | ABBVIE INC. | $1,968.03 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396917 |
| Principal investigator 1 | ABBVIE INC. | $2,408.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396919 |
| Principal investigator 1 | ABBVIE INC. | $3,002.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396921 |
| Principal investigator 1 | ABBVIE INC. | $2,408.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396929 |
| Principal investigator 1 | ABBVIE INC. | $4,209.17 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396931 |
| Principal investigator 1 | ABBVIE INC. | $1,691.28 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396933 |
| Principal investigator 1 | ABBVIE INC. | $2,718.77 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396935 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396937 |
| Principal investigator 1 | ABBVIE INC. | $1,552.50 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396939 |
| Principal investigator 1 | ABBVIE INC. | $1,113.75 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396941 |
| Principal investigator 1 | ABBVIE INC. | $1,034.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396943 |
| Principal investigator 1 | ABBVIE INC. | $1,968.03 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396945 |
| Principal investigator 1 | ABBVIE INC. | $3,002.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396947 |
| Principal investigator 1 | ABBVIE INC. | $3,002.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396957 |
| Principal investigator 1 | ABBVIE INC. | $1,472.85 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396959 |
| Principal investigator 1 | ABBVIE INC. | $1,034.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396961 |
| Principal investigator 1 | ABBVIE INC. | $2,062.53 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396963 |
| Principal investigator 1 | ABBVIE INC. | $4,209.17 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396965 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396967 |
| Principal investigator 1 | ABBVIE INC. | $1,691.28 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396969 |
| Principal investigator 1 | ABBVIE INC. | $2,408.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396971 |
| Principal investigator 1 | ABBVIE INC. | $1,034.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396973 |
| Principal investigator 1 | ABBVIE INC. | $4,209.17 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396975 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396977 |
| Principal investigator 1 | ABBVIE INC. | $2,408.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396989 |
| Principal investigator 1 | ABBVIE INC. | $1,208.25 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396991 |
| Principal investigator 1 | ABBVIE INC. | $1,208.25 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396993 |
| Principal investigator 1 | ABBVIE INC. | $1,472.85 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396995 |
| Principal investigator 1 | ABBVIE INC. | $1,968.03 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396997 |
| Principal investigator 1 | ABBVIE INC. | $2,062.53 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396999 |
| Principal investigator 1 | ABBVIE INC. | $1,034.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397001 |
| Principal investigator 1 | ABBVIE INC. | $2,941.52 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397003 |
| Principal investigator 1 | ABBVIE INC. | $1,968.03 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397005 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397009 |
| Principal investigator 1 | ABBVIE INC. | $4,209.17 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397021 |
| Principal investigator 1 | ABBVIE INC. | $1,113.75 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397023 |
| Principal investigator 1 | ABBVIE INC. | $1,113.75 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397025 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397027 |
| Principal investigator 1 | ABBVIE INC. | $2,718.77 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397029 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397031 |
| Principal investigator 1 | ABBVIE INC. | $2,718.77 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397037 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397039 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397041 |
| Principal investigator 1 | ABBVIE INC. | $2,813.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397043 |
| Principal investigator 1 | ABBVIE INC. | $2,537.87 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397045 |
| Principal investigator 1 | ABBVIE INC. | $4,209.17 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397047 |
| Principal investigator 1 | ABBVIE INC. | $2,941.52 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397049 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397051 |
| Principal investigator 1 | ABBVIE INC. | $1,552.50 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397053 |
| Principal investigator 1 | ABBVIE INC. | $1,552.50 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397055 |
| Principal investigator 1 | ABBVIE INC. | $2,718.77 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397057 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397059 |
| Principal investigator 1 | ABBVIE INC. | $1,196.10 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397061 |
| Principal investigator 1 | ABBVIE INC. | $2,408.27 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397063 |
| Principal investigator 1 | ABBVIE INC. | $1,968.03 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397065 |
| Principal investigator 1 | ABBVIE INC. | $1,691.28 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397067 |
| Principal investigator 1 | ABBVIE INC. | $2,718.77 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397069 |
| Principal investigator 1 | ABBVIE INC. | $1,113.75 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397071 |
| Principal investigator 1 | ABBVIE INC. | $1,472.85 | 08/25/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998397073 |
| Principal investigator 1 | PFIZER INC. | $34,910.04 | 08/25/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046421487 |
| Principal investigator 1 | ABBVIE INC. | $125.35 | 08/21/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396245 |
| Principal investigator 1 | ABBVIE INC. | $125.35 | 08/21/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396247 |
| Principal investigator 1 | ABBVIE INC. | $125.35 | 08/21/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396253 |
| Principal investigator 1 | ABBVIE INC. | $125.35 | 08/21/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396261 |
| Principal investigator 1 | ABBVIE INC. | $125.35 | 08/21/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998396265 |
| Principal investigator 1 | PFIZER INC. | $16,837.92 | 08/14/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046374983 |
| Principal investigator 1 | PFIZER INC. | $17,508.68 | 08/14/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046376921 |
| Principal investigator 1 | PFIZER INC. | $325.00 | 08/14/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046377523 |
| Principal investigator 1 | PFIZER INC. | $5,460.41 | 08/11/2023 | Non-covered Recipient Entity START Midwest LLC | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046422303 |
| Principal investigator 1 | ABBVIE INC. | $4,749.17 | 08/07/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998393415 |
| Principal investigator 1 | PFIZER INC. | $4,609.58 | 08/05/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046417223 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $7,572.00 | 08/04/2023 | Non-covered Recipient Entity MULTIPLE DOCTORS | AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD | No dispute reported | 06/30/2026 | 1006132827 |
| Principal investigator 1 | MACROGENICS, INC. | $7,644.97 | 08/01/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043827185 |
| Principal investigator 1 | MACROGENICS, INC. | $3,253.18 | 08/01/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043827197 |
| Principal investigator 1 | MACROGENICS, INC. | $5,367.75 | 08/01/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043827211 |
| Principal investigator 1 | PFIZER INC. | $325.00 | 08/01/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046375803 |
| Principal investigator 1 | PFIZER INC. | $72,318.61 | 07/26/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046408529 |
| Principal investigator 1 | PFIZER INC. | $20,903.43 | 07/25/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046410337 |
| Principal investigator 1 | PFIZER INC. | $15,438.61 | 07/25/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046485361 |
| Principal investigator 1 | PFIZER INC. | $108.00 | 07/24/2023 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046377659 |
| Principal investigator 1 | PFIZER INC. | $14,104.97 | 07/24/2023 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046380651 |
| Principal investigator 1 | PFIZER INC. | $325.00 | 07/19/2023 | Non-covered Recipient Entity START Midwest | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046376501 |
| Principal investigator 1 | PFIZER INC. | $19,134.00 | 07/17/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046367677 |
| Principal investigator 1 | PFIZER INC. | $35,017.36 | 07/17/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046376557 |
| Principal investigator 1 | Genmab U.S., Inc. | $4,981.50 | 07/13/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392159 |
| Principal investigator 1 | PFIZER INC. | $36.00 | 07/12/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046376487 |
| Principal investigator 1 | PFIZER INC. | $650.00 | 07/12/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046376543 |
| Principal investigator 1 | PFIZER INC. | $14,104.97 | 07/11/2023 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046377551 |
| Principal investigator 1 | PFIZER INC. | $325.00 | 07/11/2023 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046380025 |
| Principal investigator 1 | PFIZER INC. | $54.00 | 07/11/2023 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046380829 |
| Principal investigator 1 | PFIZER INC. | $40,497.01 | 07/11/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046409183 |
| Principal investigator 1 | PFIZER INC. | $1,300.00 | 07/10/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046377537 |
| Principal investigator 1 | PFIZER INC. | $29,862.35 | 07/08/2023 | Non-covered Recipient Entity START Midwest LLC | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046498212 |
| Principal investigator 1 | MACROGENICS, INC. | $5,483.15 | 07/03/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043824319 |
| Principal investigator 1 | MACROGENICS, INC. | $2,333.26 | 07/03/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043824333 |
| Principal investigator 1 | MACROGENICS, INC. | $3,849.87 | 07/03/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043824347 |
| Principal investigator 1 | Genmab U.S., Inc. | $654.08 | 06/28/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392053 |
| Principal investigator 1 | Genmab U.S., Inc. | $337.50 | 06/28/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392109 |
| Principal investigator 1 | PFIZER INC. | $1,625.00 | 06/21/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046468625 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,092.00 | 06/14/2023 | Non-covered Recipient Entity MULTIPLE DOCTORS | AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD | No dispute reported | 06/30/2026 | 1006132795 |
| Principal investigator 1 | PFIZER INC. | $35,017.36 | 06/13/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046492265 |
| Principal investigator 1 | PFIZER INC. | $15,307.20 | 06/13/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046495071 |
| Principal investigator 1 | ABBVIE INC. | $60.75 | 06/09/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998386563 |
| Principal investigator 1 | ABBVIE INC. | $94.50 | 06/09/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998386565 |
| Principal investigator 1 | ABBVIE INC. | $25.00 | 06/09/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998386567 |
| Principal investigator 1 | ABBVIE INC. | $438.75 | 06/09/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998386569 |
| Principal investigator 1 | ABBVIE INC. | $270.00 | 06/09/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998386571 |
| Principal investigator 1 | ABBVIE INC. | $60.75 | 06/09/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998386573 |
| Principal investigator 1 | ABBVIE INC. | $14.12 | 06/09/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998386575 |
| Principal investigator 1 | ABBVIE INC. | $20.00 | 06/09/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998386577 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 06/09/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998386579 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 06/09/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998386581 |
| Principal investigator 1 | ABBVIE INC. | $250.00 | 06/09/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998386587 |
| Principal investigator 1 | ABBVIE INC. | $438.75 | 06/09/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998386589 |
| Principal investigator 1 | ABBVIE INC. | $79.65 | 06/09/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998386591 |
| Principal investigator 1 | ABBVIE INC. | $17.51 | 06/09/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998386593 |
| Principal investigator 1 | ABBVIE INC. | $128.25 | 06/09/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998386595 |
| Principal investigator 1 | ABBVIE INC. | $67.50 | 06/09/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998386597 |
| Principal investigator 1 | MACROGENICS, INC. | $7,256.18 | 06/09/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043823967 |
| Principal investigator 1 | MACROGENICS, INC. | $3,087.74 | 06/09/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043823979 |
| Principal investigator 1 | MACROGENICS, INC. | $5,094.77 | 06/09/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043823995 |
| Principal investigator 1 | PFIZER INC. | $81.00 | 06/07/2023 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046492457 |
| Principal investigator 1 | PFIZER INC. | $24,536.00 | 06/07/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS | No dispute reported | 06/30/2026 | 1046495045 |
| Principal investigator 1 | PFIZER INC. | $1,625.00 | 06/05/2023 | Non-covered Recipient Entity START Midwest | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046466277 |
| Principal investigator 1 | PFIZER INC. | $9,001.81 | 06/03/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046531879 |
| Principal investigator 1 | PFIZER INC. | $24,430.98 | 06/03/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046532505 |
| Principal investigator 1 | PFIZER INC. | $2,722.95 | 06/02/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1046513025 |
| Recipient | PFIZER INC. | $940.00 | 06/02/2023 | Covered Recipient Physician | PF06804103 MAVELERTINIB PF4136309 PF06952229 NIROGACESTAT PF06671008 ARRY 382 PF04691502 PF06821497 PF06939999 PF06840003 PF07265807 COFETUZUMAB PELIDOTIN MULTI PRODUCT UTOMILUMAB GEDATOLISIB ELRANATAMAB PF067535 CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1061083249 |
| Recipient | PFIZER INC. | $940.00 | 06/02/2023 | Covered Recipient Physician | PF06804103 MAVELERTINIB PF4136309 PF06952229 NIROGACESTAT PF06671008 ARRY 382 PF04691502 PF06821497 PF06939999 PF06840003 PF07265807 COFETUZUMAB PELIDOTIN MULTI PRODUCT UTOMILUMAB GEDATOLISIB ELRANATAMAB PF067535 CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1061083499 |
| Recipient | PFIZER INC. | $940.00 | 06/02/2023 | Covered Recipient Physician | PF06804103 MAVELERTINIB PF4136309 PF06952229 NIROGACESTAT PF06671008 ARRY 382 PF04691502 PF06821497 PF06939999 PF06840003 PF07265807 COFETUZUMAB PELIDOTIN MULTI PRODUCT UTOMILUMAB GEDATOLISIB ELRANATAMAB PF067535 CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1061083501 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,000.00 | 05/25/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392059 |
| Principal investigator 1 | PFIZER INC. | $20,472.00 | 05/25/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046374289 |
| Principal investigator 1 | PFIZER INC. | $3,170.48 | 05/25/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046439455 |
| Principal investigator 1 | PFIZER INC. | $15,269.55 | 05/25/2023 | Non-covered Recipient Entity START Midwest LLC | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046523979 |
| Principal investigator 1 | ABBVIE INC. | $2,934.77 | 05/22/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998384105 |
| Principal investigator 1 | PFIZER INC. | $650.00 | 05/16/2023 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046463857 |
| Principal investigator 1 | PFIZER INC. | $18.00 | 05/16/2023 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046492245 |
| Principal investigator 1 | PFIZER INC. | $17,508.68 | 05/15/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046466297 |
| Principal investigator 1 | PFIZER INC. | $19,134.00 | 05/15/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046490747 |
| Principal investigator 1 | Genmab U.S., Inc. | $200.00 | 05/11/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392041 |
| Principal investigator 1 | Genmab U.S., Inc. | $405.00 | 05/11/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392079 |
| Principal investigator 1 | MACROGENICS, INC. | $1,212.60 | 05/10/2023 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST | MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER | No dispute reported | 06/30/2026 | 1043816757 |
| Principal investigator 1 | MACROGENICS, INC. | $516.00 | 05/10/2023 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST | MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER | No dispute reported | 06/30/2026 | 1043816771 |
| Principal investigator 1 | MACROGENICS, INC. | $851.40 | 05/10/2023 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST | MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER | No dispute reported | 06/30/2026 | 1043816785 |
| Principal investigator 1 | MACROGENICS, INC. | $1,598.56 | 05/10/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043816797 |
| Principal investigator 1 | MACROGENICS, INC. | $680.24 | 05/10/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043816811 |
| Principal investigator 1 | MACROGENICS, INC. | $1,122.40 | 05/10/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043816823 |
| Principal investigator 1 | PFIZER INC. | $124,151.83 | 05/10/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046434597 |
| Principal investigator 1 | PFIZER INC. | $18,095.86 | 05/06/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046521247 |
| Principal investigator 1 | PFIZER INC. | $14,062.62 | 05/06/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046525451 |
| Principal investigator 1 | Exelixis Inc. | $1,310.00 | 05/05/2023 | Non-covered Recipient Entity START MidWest LLC | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1041947197 |
| Principal investigator 1 | Exelixis Inc. | $1,020.00 | 05/05/2023 | Non-covered Recipient Entity START MidWest LLC | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1041947203 |
| Principal investigator 1 | Exelixis Inc. | $1,352.00 | 05/05/2023 | Non-covered Recipient Entity START MidWest LLC | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1041947211 |
| Principal investigator 1 | Genmab U.S., Inc. | $2,204.55 | 05/04/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038391999 |
| Principal investigator 1 | Genmab U.S., Inc. | $150.00 | 05/04/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392153 |
| Principal investigator 1 | ABBVIE INC. | $2,516.27 | 05/03/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998380267 |
| Principal investigator 1 | ABBVIE INC. | $2,435.27 | 05/03/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998380269 |
| Principal investigator 1 | ABBVIE INC. | $3,337.08 | 05/03/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998380275 |
| Principal investigator 1 | ABBVIE INC. | $2,610.77 | 05/03/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998380287 |
| Principal investigator 1 | ABBVIE INC. | $1,499.85 | 05/03/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998380289 |
| Principal investigator 1 | ABBVIE INC. | $3,812.27 | 05/03/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998380295 |
| Principal investigator 1 | ABBVIE INC. | $2,366.28 | 05/03/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998380311 |
| Principal investigator 1 | ABBVIE INC. | $2,934.77 | 05/03/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998380313 |
| Principal investigator 1 | ABBVIE INC. | $2,934.77 | 05/03/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998380315 |
| Principal investigator 1 | ABBVIE INC. | $2,366.28 | 05/03/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998380317 |
| Principal investigator 1 | ABBVIE INC. | $1,499.85 | 05/03/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998380319 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 05/01/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998379965 |
| Principal investigator 1 | ABBVIE INC. | $2,934.77 | 05/01/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998379967 |
| Principal investigator 1 | ABBVIE INC. | $2,934.77 | 05/01/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998379969 |
| Principal investigator 1 | ABBVIE INC. | $500.85 | 05/01/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998379971 |
| Principal investigator 1 | ABBVIE INC. | $2,713.37 | 05/01/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998379975 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 04/26/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998379523 |
| Principal investigator 1 | Genmab U.S., Inc. | $337.50 | 04/26/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392097 |
| Principal investigator 1 | MACROGENICS, INC. | $4,673.00 | 04/26/2023 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST | MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER | No dispute reported | 06/30/2026 | 1043816493 |
| Principal investigator 1 | PFIZER INC. | $18,351.10 | 04/25/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046440351 |
| Principal investigator 1 | PFIZER INC. | $2,380.00 | 04/22/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1046435537 |
| Principal investigator 1 | PFIZER INC. | $14,942.59 | 04/22/2023 | Non-covered Recipient Entity START Midwest LLC | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046477149 |
| Principal investigator 1 | Genmab U.S., Inc. | $274.73 | 04/20/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392011 |
| Principal investigator 1 | Genmab U.S., Inc. | $274.73 | 04/20/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392128 |
| Principal investigator 1 | Eli Lilly and Company | $8,075.00 | 04/18/2023 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS LLC | A PHASE 1 MULTICENTER GLOBAL FIRST IN HUMAN STUDY OF THE CD73 INHIBITOR LY3475070 AS MONOTHERAPY OR IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1038137361 |
| Principal investigator 1 | PFIZER INC. | $10,509.77 | 04/14/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046477853 |
| Principal investigator 1 | Genmab U.S., Inc. | $150.00 | 04/13/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392023 |
| Principal investigator 1 | Genmab U.S., Inc. | $2,313.90 | 04/13/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392147 |
| Principal investigator 1 | PFIZER INC. | $45.00 | 04/13/2023 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046490771 |
| Principal investigator 1 | PFIZER INC. | $28,209.94 | 04/13/2023 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046492415 |
| Principal investigator 1 | Exelixis Inc. | $10,810.00 | 04/12/2023 | Non-covered Recipient Entity START MidWest LLC | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1041947219 |
| Principal investigator 1 | MACROGENICS, INC. | $618.64 | 04/12/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043798159 |
| Principal investigator 1 | MACROGENICS, INC. | $263.25 | 04/12/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043798169 |
| Principal investigator 1 | MACROGENICS, INC. | $434.36 | 04/12/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043798179 |
| Principal investigator 1 | PFIZER INC. | $21,971.20 | 04/12/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046438531 |
| Principal investigator 1 | PFIZER INC. | $33,800.13 | 04/12/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046438559 |
| Principal investigator 1 | PFIZER INC. | $18,417.89 | 04/12/2023 | Non-covered Recipient Entity START Midwest LLC | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046475675 |
| Principal investigator 1 | PFIZER INC. | $1,950.00 | 04/12/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046492435 |
| Principal investigator 1 | PFIZER INC. | $1,625.00 | 04/10/2023 | Non-covered Recipient Entity START Midwest | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046464185 |
| Principal investigator 1 | PFIZER INC. | $650.00 | 04/10/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046492569 |
| Principal investigator 1 | PFIZER INC. | $2,050.70 | 04/07/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1046476935 |
| Principal investigator 1 | ABBVIE INC. | $2,340.00 | 04/05/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998376997 |
| Principal investigator 1 | Exelixis Inc. | $203.00 | 03/31/2023 | Non-covered Recipient Entity START MidWest LLC | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1041947127 |
| Principal investigator 1 | MACROGENICS, INC. | $1,828.82 | 03/30/2023 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST | MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER | No dispute reported | 06/30/2026 | 1043797839 |
| Principal investigator 1 | PFIZER INC. | $19,134.00 | 03/29/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046466853 |
| Principal investigator 1 | PFIZER INC. | $35,017.36 | 03/29/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046467023 |
| Principal investigator 1 | PFIZER INC. | $650.00 | 03/27/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046468557 |
| Principal investigator 1 | PFIZER INC. | $199,588.63 | 03/25/2023 | Non-covered Recipient Entity START Midwest LLC | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046451868 |
| Principal investigator 1 | PFIZER INC. | $14,552.68 | 03/24/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046448873 |
| Principal investigator 1 | PFIZER INC. | $25,682.07 | 03/24/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046456741 |
| Principal investigator 1 | PFIZER INC. | $10,647.10 | 03/24/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1046546739 |
| Principal investigator 1 | PFIZER INC. | $27.00 | 03/22/2023 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046466509 |
| Principal investigator 1 | Exelixis Inc. | $1,054.00 | 03/20/2023 | Non-covered Recipient Entity START MidWest LLC | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1041947143 |
| Principal investigator 1 | Exelixis Inc. | $720.00 | 03/20/2023 | Non-covered Recipient Entity START MidWest LLC | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1041947175 |
| Principal investigator 1 | MACROGENICS, INC. | $6,435.24 | 03/17/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043797551 |
| Principal investigator 1 | MACROGENICS, INC. | $2,738.40 | 03/17/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043797559 |
| Principal investigator 1 | MACROGENICS, INC. | $4,518.36 | 03/17/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043797571 |
| Principal investigator 1 | Genmab U.S., Inc. | $3,157.65 | 03/16/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392115 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 03/15/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998373789 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 03/15/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998373795 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 03/15/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998373797 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 03/15/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998373805 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 03/15/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998373807 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 03/15/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998373809 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 03/15/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998373819 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 03/15/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998373821 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 03/15/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998373823 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 03/15/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998373825 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 03/15/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998373831 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 03/15/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998373833 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 03/15/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998373841 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 03/15/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998373843 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 03/15/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998373845 |
| Principal investigator 1 | PFIZER INC. | $1,625.00 | 03/13/2023 | Non-covered Recipient Entity START Midwest | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046494003 |
| Principal investigator 1 | Genmab U.S., Inc. | $654.08 | 03/09/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392085 |
| Principal investigator 1 | ABBVIE INC. | $36.18 | 03/08/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998372691 |
| Principal investigator 1 | ABBVIE INC. | $36.18 | 03/08/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998372699 |
| Principal investigator 1 | ABBVIE INC. | $27.41 | 03/08/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998372713 |
| Principal investigator 1 | ABBVIE INC. | $1,925.00 | 03/08/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998372719 |
| Principal investigator 1 | ABBVIE INC. | $2,920.00 | 03/08/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998372731 |
| Principal investigator 1 | ABBVIE INC. | $27.41 | 03/08/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998372733 |
| Principal investigator 1 | PFIZER INC. | $9,061.88 | 03/07/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046448213 |
| Principal investigator 1 | PFIZER INC. | $21,046.00 | 03/07/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1046458233 |
| Principal investigator 1 | PFIZER INC. | $18,019.65 | 03/04/2023 | Non-covered Recipient Entity START Midwest LLC | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046446775 |
| Principal investigator 1 | PFIZER INC. | $2,200.00 | 03/04/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS | No dispute reported | 06/30/2026 | 1046447093 |
| Principal investigator 1 | PFIZER INC. | $1,350.00 | 03/04/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046544599 |
| Principal investigator 1 | Genmab U.S., Inc. | $350.00 | 03/03/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392071 |
| Principal investigator 1 | Genmab U.S., Inc. | $405.00 | 03/03/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392091 |
| Principal investigator 1 | ABBVIE INC. | $450.00 | 03/01/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998371999 |
| Principal investigator 1 | PFIZER INC. | $17,985.50 | 02/25/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1046368397 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 02/24/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998371823 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 02/24/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998371825 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 02/24/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998371827 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 02/24/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998371829 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 02/24/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998371831 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 02/24/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998371833 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 02/24/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998371835 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 02/24/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998371837 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 02/24/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998371839 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 02/24/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998371841 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 02/24/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998371843 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 02/24/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998371889 |
| Principal investigator 1 | Exelixis Inc. | $2,751.00 | 02/24/2023 | Non-covered Recipient Entity START MidWest LLC | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1041947093 |
| Principal investigator 1 | PFIZER INC. | $18,152.78 | 02/24/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046453551 |
| Principal investigator 1 | PFIZER INC. | $33,003.34 | 02/24/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046459943 |
| Principal investigator 1 | Genmab U.S., Inc. | $4,071.60 | 02/23/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392005 |
| Principal investigator 1 | MACROGENICS, INC. | $5,558.15 | 02/23/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043797113 |
| Principal investigator 1 | MACROGENICS, INC. | $2,365.17 | 02/23/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043797125 |
| Principal investigator 1 | MACROGENICS, INC. | $3,902.53 | 02/23/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043797135 |
| Principal investigator 1 | PFIZER INC. | $17,508.68 | 02/22/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046466213 |
| Principal investigator 1 | PFIZER INC. | $19,134.00 | 02/22/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046490057 |
| Principal investigator 1 | PFIZER INC. | $27.00 | 02/20/2023 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046466463 |
| Principal investigator 1 | PFIZER INC. | $14,104.97 | 02/20/2023 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046498409 |
| Principal investigator 1 | Genmab U.S., Inc. | $202.50 | 02/16/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392029 |
| Principal investigator 1 | Genmab U.S., Inc. | $250.00 | 02/16/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392035 |
| Principal investigator 1 | Genmab U.S., Inc. | $4,981.50 | 02/16/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392135 |
| Principal investigator 1 | Exelixis Inc. | $714.00 | 02/15/2023 | Non-covered Recipient Entity START MidWest LLC | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1041947079 |
| Principal investigator 1 | Exelixis Inc. | $655.00 | 02/15/2023 | Non-covered Recipient Entity START MidWest LLC | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1041947109 |
| Principal investigator 1 | Exelixis Inc. | $405.00 | 02/15/2023 | Non-covered Recipient Entity START MidWest LLC | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1041947183 |
| Principal investigator 1 | MACROGENICS, INC. | $78.00 | 02/14/2023 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST | MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER | No dispute reported | 06/30/2026 | 1043793013 |
| Recipient | PFIZER INC. | $330.00 | 02/13/2023 | Covered Recipient Physician | ELRANATAMAB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1046527817 |
| Recipient | PFIZER INC. | $330.00 | 02/13/2023 | Covered Recipient Physician | ELRANATAMAB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1046527837 |
| Recipient | PFIZER INC. | $330.00 | 02/13/2023 | Covered Recipient Physician | ELRANATAMAB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1046531195 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $121,583.00 | 02/10/2023 | Non-covered Recipient Entity Start Midwest | PhI/II TIGIT BiSpec combo (Nivo/NG CTLA4) safety & NSCLC expansion - A Phase 1b/2 Study of BMS-986442 in Combination with Nivolumab or Nivolumab and Chemotherapies in Participants with Advanced Solid Tumors and Non-small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1027454885 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,053.66 | 02/08/2023 | Non-covered Recipient Entity CANCER AND HEMATOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | No dispute reported | 06/30/2026 | 991133783 |
| Principal investigator 1 | Exelixis Inc. | $2,751.00 | 02/08/2023 | Non-covered Recipient Entity START MidWest LLC | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1041947119 |
| Principal investigator 1 | Exelixis Inc. | $5,270.65 | 02/08/2023 | Non-covered Recipient Entity START MidWest LLC | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1041947135 |
| Principal investigator 1 | ABBVIE INC. | $67.50 | 02/06/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998368787 |
| Principal investigator 1 | ABBVIE INC. | $114.75 | 02/06/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998368789 |
| Principal investigator 1 | PFIZER INC. | $3,631.85 | 02/04/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046496449 |
| Principal investigator 1 | PFIZER INC. | $3,030.41 | 02/03/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046457845 |
| Principal investigator 1 | PFIZER INC. | $4,372.05 | 02/03/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL DOSE ESCALATION AND EXPANSION STUDY OF PF07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 1046462435 |
| Principal investigator 1 | PFIZER INC. | $33,682.35 | 02/03/2023 | Non-covered Recipient Entity START Midwest LLC | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046462593 |
| Principal investigator 1 | ABBVIE INC. | $1,930.16 | 01/30/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998367749 |
| Principal investigator 1 | ABBVIE INC. | $4,291.31 | 01/30/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998367751 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 01/30/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998367753 |
| Principal investigator 1 | ABBVIE INC. | $2,267.66 | 01/30/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998367755 |
| Principal investigator 1 | ABBVIE INC. | $500.85 | 01/30/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998367757 |
| Principal investigator 1 | ABBVIE INC. | $1,036.00 | 01/30/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998367759 |
| Principal investigator 1 | ABBVIE INC. | $2,551.16 | 01/30/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998367761 |
| Principal investigator 1 | ABBVIE INC. | $2,362.16 | 01/30/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998367763 |
| Principal investigator 1 | ABBVIE INC. | $364.50 | 01/30/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998367767 |
| Principal investigator 1 | ABBVIE INC. | $1,979.10 | 01/30/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998367769 |
| Principal investigator 1 | ABBVIE INC. | $3,589.31 | 01/30/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998367771 |
| Principal investigator 1 | ABBVIE INC. | $2,462.06 | 01/30/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998367773 |
| Principal investigator 1 | PFIZER INC. | $1,950.00 | 01/30/2023 | Non-covered Recipient Entity START Midwest | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046485423 |
| Principal investigator 1 | Exelixis Inc. | $675.00 | 01/27/2023 | Non-covered Recipient Entity START MidWest LLC | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1041947101 |
| Principal investigator 1 | Exelixis Inc. | $2,751.30 | 01/27/2023 | Non-covered Recipient Entity START MidWest LLC | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1041947151 |
| Principal investigator 1 | Exelixis Inc. | $74.25 | 01/27/2023 | Non-covered Recipient Entity START MidWest LLC | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1041947159 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,000.00 | 01/26/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392065 |
| Principal investigator 1 | Genmab U.S., Inc. | $1,925.00 | 01/26/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392121 |
| Principal investigator 1 | Genmab U.S., Inc. | $274.73 | 01/26/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392139 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,200.00 | 01/25/2023 | Non-covered Recipient Entity MULTIPLE DOCTORS | AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD | No dispute reported | 06/30/2026 | 1006132817 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $600.00 | 01/25/2023 | Non-covered Recipient Entity MULTIPLE DOCTORS | AN OPEN-LABEL, RANDOMIZED-SEQUENCE, MULTICENTER, SINGLE-CROSSOVER STUD | No dispute reported | 06/30/2026 | 1006132849 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $27,481.28 | 01/24/2023 | Non-covered Recipient Entity Start Midwest | Phase I/II TIM3 FIH Monotherapy/Nivo Combination in advanced solid tumors | No dispute reported | 06/30/2026 | 1027454873 |
| Principal investigator 1 | PFIZER INC. | $35,017.36 | 01/24/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046495939 |
| Principal investigator 1 | PFIZER INC. | $15,307.20 | 01/24/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046498425 |
| Principal investigator 1 | PFIZER INC. | $2,888.33 | 01/24/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046537723 |
| Principal investigator 1 | PFIZER INC. | $723.60 | 01/24/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF PF07284892 ARRY558 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046537929 |
| Principal investigator 1 | PFIZER INC. | $16,709.64 | 01/24/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046544207 |
| Principal investigator 1 | ABBVIE INC. | $2,340.00 | 01/23/2023 | Non-covered Recipient Entity START MIDWEST LLC | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 | No dispute reported | 06/30/2026 | 998367145 |
| Principal investigator 1 | Exelixis Inc. | $663.00 | 01/23/2023 | Non-covered Recipient Entity START MidWest LLC | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1041947167 |
| Principal investigator 1 | PFIZER INC. | $3,846.15 | 01/21/2023 | Non-covered Recipient Entity START Midwest LLC | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046542093 |
| Principal investigator 1 | MACROGENICS, INC. | $104.00 | 01/17/2023 | Non-covered Recipient Entity SOUTH TEXAS ACCELERATED RESEARCH THERAPEUTICS START MIDWEST | MGD019 DART PROTEIN IN UNRESECTABLE METASTATIC CANCER | No dispute reported | 06/30/2026 | 1043792517 |
| Principal investigator 1 | MACROGENICS, INC. | $17,133.40 | 01/17/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043792527 |
| Principal investigator 1 | MACROGENICS, INC. | $7,290.81 | 01/17/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043792537 |
| Principal investigator 1 | MACROGENICS, INC. | $12,029.84 | 01/17/2023 | Non-covered Recipient Entity START MIDWEST LLC | A STUDY OF MGD024 IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | No dispute reported | 06/30/2026 | 1043792547 |
| Principal investigator 1 | PFIZER INC. | $18.00 | 01/16/2023 | Non-covered Recipient Entity START Midwest | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046487833 |
| Principal investigator 1 | Exelixis Inc. | $74.25 | 01/13/2023 | Non-covered Recipient Entity START MidWest LLC | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1041947085 |
| Principal investigator 1 | Exelixis Inc. | $81.00 | 01/13/2023 | Non-covered Recipient Entity START MidWest LLC | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1041947191 |
| Principal investigator 1 | Genmab U.S., Inc. | $405.00 | 01/12/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392017 |
| Principal investigator 1 | Genmab U.S., Inc. | $4,071.60 | 01/12/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392047 |
| Principal investigator 1 | Genmab U.S., Inc. | $250.00 | 01/12/2023 | Non-covered Recipient Entity THE START CENTER FOR CANCER CARE | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors. | No dispute reported | 06/30/2026 | 1038392103 |
| Principal investigator 1 | PFIZER INC. | $1,300.00 | 01/10/2023 | Non-covered Recipient Entity START Midwest | A PHASE 1B2 OPENLABEL MULTICENTER DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 IN COMBINATION WITH PF07104091 PLUS ENDOCRINE THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046468537 |
| Principal investigator 1 | PFIZER INC. | $42,734.25 | 01/07/2023 | Non-covered Recipient Entity START Midwest LLC | A PHASE 11B STUDY EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTITUMOR ACTIVITY OF PF07220060 AS A SINGLE AGENT AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1046538881 |
| Principal investigator 1 | PFIZER INC. | $167.00 | 01/06/2023 | Non-covered Recipient Entity START Midwest LLC | PHASE 12A DOSE ESCALATION FINDING AND EXPANSION STUDY EVALUATING SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF07104091 AS A SINGLE AGENT AND IN COMBINATION THERAPY | No dispute reported | 06/30/2026 | 1046545609 |